Patients With Type 1 or Type 2 DiabetesDiatolepsyNCT02080741
Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile
A study testing Blood sample of 12 ml in people with Patients With Type 1 or Type 2 Diabetes and Patients With a Type A or B Behaviour Profile, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
This study will include 100 patients with Type 1 and Type 2 diabetes, split into 2 groups of 50 patients according to their behaviour type, and their adaptation to different factors of stress encountered in their lives: the first group will consist of patients with a characteristic Type A behaviour profile, that is to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Patients With Type 1 or Type 2 Diabetes, Patients With a Type A or B Behaviour Profile
- What is being tested?
- Blood sample of 12 ml
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 57 participants
- Where
- 1 siteFrance
- Study dates
- 23 Sep 2014to 29 May 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who have provided written informed consent
- Patients with type 1 or type 2 diabetes
- Patient admitted for a consultation, as out or in-patients to the Endocrinology-Diabetology-Metabolic diseases department of Dijon CHU
- Patient > 18 years
- Patient with either a characteristic Type A behaviour profile (Bortner > 210), or a characteristic Type B behaviour profile (Bortner<154)
Who cannot join
- Persons not covered by national health insurance
- Adults under guardianship or wards of court or not intellectually independent
- Patients without diabetes
- Patients with a mixed A/B behaviour profile (154< Bortner score <210)
- Pregnant or breast-feeding women
Trial locations and contacts
1 site in 1 country.
About this study
This study will include 100 patients with Type 1 and Type 2 diabetes, split into 2 groups of 50 patients according to their behaviour type, and their adaptation to different factors of stress encountered in their lives:
- the first group will consist of patients with a characteristic Type A behaviour profile, that is to say patients with a "proactive, impatient" behaviour pattern
- the second group will consist of patients with a characteristic Type B behaviour profile that is to say patients with a "calm, slow" behaviour pattern The objective is to know if the different behaviour patterns are associated with distinct biological markers likely to influence the evolution of the diabetes.
Read more
Participation in this study will be approximately 1h30, patients will participate ONCE ONLY:
- they will answer simple questions about their disease and then complete 3 questionnaires each with 14 items.
- they will meet a clinical psychologist for an interview lasting approximately 45 minutes recorded on an audio recorder. The consultation will be used to seek links between the psyche and the disease.
- they will provide one blood sample of 12 ml (equivalent to a soup spoon) drawn in the morning.
- Being tested
- Blood sample of 12 ml
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sample of 12 mlOther
| Study group | Role | What they receive |
|---|---|---|
| Type A behaviour profile | Other | Not described Receives: Other: Blood sample of 12 ml |
| Type B behaviour profile | Other | Not described Receives: Other: Blood sample of 12 ml |
What is being measured
The primary outcome is the main question the study is designed to answer.
Telomere length
Measured: Baselines
Secondary outcomes (1)
Level of expression of candidate genes
Measured: Baselines
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2014 (estimated)
- Study start23 Sep 2014
- Primary completion29 May 2018
Why it stopped: lack of inclusion
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Patients With Type 1 or Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 57 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02080741
- Sponsor's protocol ID
- CHAUVET-GELINIER APJ 2013
- Acronym
- Diatolepsy
- Status last verified
- Feb 2026
- First submitted
- 5 Mar 2014
- Last updated
- 9 Feb 2026
- Results posted
- No
Publications
Chauvet-Gelinier JC, Mosca-Boidron AL, Lemogne C, Ragot S, Forestier N, Callegarin D, Allard C, Rebai A, Bouillet B, Ponavoy E, Simoneau I, Petit JM, Bondolfi G, Callier P, Trojak B, Bonin B, Verges B. Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes. Diabetes Metab. 2019 Dec;45(6):582-585. doi: 10.1016/j.diabet.2018.11.005. Epub 2018 Nov 23.
PubMed 30476653
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile
- ClinicalTrials.gov ID
- NCT02080741
- Acronym / sponsor ID
- Diatolepsy / CHAUVET-GELINIER APJ 2013
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: lack of inclusion
- Enrolment
- 57 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 23 Sep 2014 (actual)
- Primary completion
- 29 May 2018 (actual)
- First posted
- 6 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will include 100 patients with Type 1 and Type 2 diabetes, split into 2 groups of 50 patients according to their behaviour type, and their adaptation to different factors of stress encountered in their lives:
- the first group will consist of patients with a characteristic Type A behaviour profile, that is to say patients with a "proactive, impatient" behaviour pattern
- the second group will consist of patients with a characteristic Type B behaviour profile that is to say patients with a "calm, slow" behaviour pattern The objective is to know if the different behaviour patterns are associated with distinct biological markers likely to influence the evolution of the diabetes.
Participation in this study will be approximately 1h30, patients will participate ONCE ONLY:
- they will answer simple questions about their disease and then complete 3 questionnaires each with 14 items.
- they will meet a clinical psychologist for an interview lasting approximately 45 minutes recorded on an audio recorder. The consultation will be used to seek links between the psyche and the disease.
- they will provide one blood sample of 12 ml (equivalent to a soup spoon) drawn in the morning.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Type A behaviour profile | Other | Other: Blood sample of 12 ml |
| Type B behaviour profile | Other | Other: Blood sample of 12 ml |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients who have provided written informed consent
- Patients with type 1 or type 2 diabetes
- Patient admitted for a consultation, as out or in-patients to the Endocrinology-Diabetology-Metabolic diseases department of Dijon CHU
- Patient > 18 years
- Patient with either a characteristic Type A behaviour profile (Bortner > 210), or a characteristic Type B behaviour profile (Bortner<154)
Key exclusion criteria (5 listed)
- Persons not covered by national health insurance
- Adults under guardianship or wards of court or not intellectually independent
- Patients without diabetes
- Patients with a mixed A/B behaviour profile (154< Bortner score <210)
- Pregnant or breast-feeding women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sample of 12 ml | Other | Type A behaviour profile, Type B behaviour profile |
Primary outcome
Telomere length
Time frame: Baselines
1 secondary outcome
Level of expression of candidate genes
Time frame: Baselines
Results and safety
The study was stopped early (reason given: lack of inclusion). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Results publication: PubMed 30476653Chauvet-Gelinier JC, Mosca-Boidron AL, Lemogne C, Ragot S, Forestier N, Callegarin D, Allard C, Rebai A, Bouillet B, Ponavoy E, Simoneau I, Petit JM, Bondolfi G, Callier P, Trojak B, Bonin B, Verges B. Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes. Diabetes Metab. 2019 Dec;45(6):582-585. doi: 10.1016/j.diabet.2018.11.005. Epub 2018 Nov 23.
Related trials for Patients With Type 1 or Type 2 Diabetes
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingPhase 1/2
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
RecruitingPhase 1/2
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Advanced Solid Tumor, Metastatic Cancer
Not yet recruiting
A Novel Miniature Equine-Assisted Diabetes Education Program for Youth: Evaluating the Diabetes Equine Empowerment Program (DEEP).
Diabetes (Insulin-requiring, Type 1 or Type 2), Pediatric Diabetes
Recruiting
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood sample of 12 ml in people with Patients With Type 1 or Type 2 Diabetes and Patients With a Type A or B Behaviour Profile, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: lack of inclusion). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Telomere length (time frame: Baselines). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02080741, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.